374 related articles for article (PubMed ID: 29703758)
1. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective.
Karamchandani DM; Chetty R
J Clin Pathol; 2018 Aug; 71(8):665-671. PubMed ID: 29703758
[TBL] [Abstract][Full Text] [Related]
2. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
Cramer P; Bresalier RS
Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
5. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
6. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
8. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
9. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis.
Khan J; Katona T
Cureus; 2021 Sep; 13(9):e18085. PubMed ID: 34692300
[TBL] [Abstract][Full Text] [Related]
11. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.
Chen JH; Pezhouh MK; Lauwers GY; Masia R
Am J Surg Pathol; 2017 May; 41(5):643-654. PubMed ID: 28296676
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.
Wright AP; Piper MS; Bishu S; Stidham RW
Aliment Pharmacol Ther; 2019 Jun; 49(12):1474-1483. PubMed ID: 31035308
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Assarzadegan N; Montgomery E; Anders RA
Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108
[TBL] [Abstract][Full Text] [Related]
16. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.
Adler BL; Pezhouh MK; Kim A; Luan L; Zhu Q; Gani F; Yarchoan M; Chen J; Voltaggio L; Parian A; Lazarev M; Lauwers GY; Pawlik TM; Montgomery EA; Jaffee E; Le DT; Taube JM; Anders RA
J Intern Med; 2018 Jun; 283(6):568-577. PubMed ID: 29464806
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy.
Zen Y; Yeh MM
Semin Diagn Pathol; 2019 Nov; 36(6):434-440. PubMed ID: 31358424
[TBL] [Abstract][Full Text] [Related]
18. [Immune-related adverse events by immune checkpoint inhibitors].
Kadono T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
[No Abstract] [Full Text] [Related]
20. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.
Dougan M; Wang Y; Rubio-Tapia A; Lim JK
Gastroenterology; 2021 Mar; 160(4):1384-1393. PubMed ID: 33080231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]